PT - JOURNAL ARTICLE AU - Ujma, Péter Przemyslaw AU - Bódizs, Róbert TI - Sleep alterations as a function of 88 health indicators AID - 10.1101/2023.11.20.23298781 DP - 2023 Jan 01 TA - medRxiv PG - 2023.11.20.23298781 4099 - http://medrxiv.org/content/early/2023/11/20/2023.11.20.23298781.short 4100 - http://medrxiv.org/content/early/2023/11/20/2023.11.20.23298781.full AB - Alterations in sleep have been described in multiple health conditions and as a function of several medication effects. However, evidence generally stems from small univariate studies. Here, we apply a large-sample, data-driven approach to investigate patterns between changes in sleep macrostructure, quantitative sleep EEG and health. We use data from the MrOS Sleep Study, containing polysomnography and health data from a large sample (N=3086) of elderly American men to establish associations between sleep macrostructure, the spectral composition of the electroencephalogram, 38 medical disorders, 2 health behaviors and the use of 48 medications. Of sleep macrostructure variables, increased REM latency and reduced REM duration was the most common finding across health indicators, along with increased sleep latency and reduced sleep efficiency. We found that the majority of health indicators were not associated with objective EEG PSD alterations. Associations with the rest were highly stereotypical, with two principal components accounting for 85-95% of the PSD-health association. PC1 consists of a decrease of slow and an increase of fast PSD components, mainly in NREM. This pattern was most strongly associated with depression/SSRI medication use and age-related disorders. PC2 consists of changes in mid-frequency activity. Increased mid-frequency activity was associated with benzodiazepine use, while decreases are associated with cardiovascular problems and associated medications, in line with immune-mediated circadian demodulation in these disorders. Specific increases in sleep spindle frequency activity were associated with taking benzodiazepines and zolpidem. Sensitivity analyses supported the presence of both disorder and medication effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA-25 funding scheme. Peter P. Ujma was supported by the National Research, Development and Innovation Office - NKFIH (grant number: 138935).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at www.sleepdata.org.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data is available from www.sleepdata.org.https://www.sleepdata.orghttps://www.zenodo.org/records/10118960